These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34331548)

  • 1. Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.
    Warner SE; Kaplan FS; Pignolo RJ; Smith SE; Hsiao EC; De Cunto C; Di Rocco M; Harnett K; Grogan D; Genant HK
    Calcif Tissue Int; 2021 Dec; 109(6):615-625. PubMed ID: 34331548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
    Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
    J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
    Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
    Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.
    Pignolo RJ; Baujat G; Brown MA; De Cunto C; Di Rocco M; Hsiao EC; Keen R; Al Mukaddam M; Sang KLQ; Wilson A; White B; Grogan DR; Kaplan FS
    Orphanet J Rare Dis; 2019 May; 14(1):98. PubMed ID: 31053156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
    Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
    Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
    Eekhoff EMW; Botman E; Coen Netelenbos J; de Graaf P; Bravenboer N; Micha D; Pals G; de Vries TJ; Schoenmaker T; Hoebink M; Lammertsma AA; Raijmakers PGHM
    Bone; 2018 Apr; 109():143-146. PubMed ID: 28826841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
    Towler OW; Shore EM; Kaplan FS
    Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
    Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
    Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
    Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
    BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
    Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
    J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural history of fibrodysplasia ossificans progressiva: A prospective, global 36-month study.
    Pignolo RJ; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Al Mukaddam M; Le Quan Sang KH; Wilson A; Marino R; Strahs A; Kaplan FS
    Genet Med; 2022 Dec; 24(12):2422-2433. PubMed ID: 36152026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: An [
    Botman E; Raijmakers PGHM; Yaqub M; Teunissen B; Netelenbos C; Lubbers W; Schwarte LA; Micha D; Bravenboer N; Schoenmaker T; de Vries TJ; Pals G; Smit JM; Koolwijk P; Trotter DG; Lammertsma AA; Eekhoff EMW
    Bone; 2019 Jul; 124():1-6. PubMed ID: 30858149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
    Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
    J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrodysplasia ossificans progressiva: Review and research activities in Japan.
    Haga N; Nakashima Y; Kitoh H; Kamizono J; Katagiri T; Saijo H; Tsukamoto S; Shinoda Y; Sawada R; Nakahara Y
    Pediatr Int; 2020 Jan; 62(1):3-13. PubMed ID: 31774601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature.
    Botman E; Netelenbos JC; Rustemeyer T; Schoonmade LJ; Nieuwenhuijzen JA; Teunissen BP; Visser M; Raijmakers P; Lammertsma AA; Dahele M; Eekhoff M
    Front Endocrinol (Lausanne); 2020; 11():6. PubMed ID: 32117050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
    Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
    BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients.
    Wang H; De Cunto CL; Pignolo RJ; Kaplan FS
    Bone; 2021 Aug; 149():115978. PubMed ID: 33915334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.